303 related articles for article (PubMed ID: 26725763)
1. Effects of Triple Therapy in Patients With Non-Valvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention Regarding Thromboembolic Risk Stratification.
Sambola A; Mutuberría M; García Del Blanco B; Alonso A; Barrabés JA; Alfonso F; Bueno H; Cequier A; Zueco J; Rodríguez-Leor O; Bosch E; Tornos P; García-Dorado D
Circ J; 2016; 80(2):354-62. PubMed ID: 26725763
[TBL] [Abstract][Full Text] [Related]
2. Predictive accuracy of CHA2DS2-VASc and HAS-BLED scores in patients without atrial fibrillation undergoing percutaneous coronary intervention and discharged on dual antiplatelet therapy.
Capodanno D; Rossini R; Musumeci G; Lettieri C; Senni M; Valsecchi O; Angiolillo DJ; Lip GY
Int J Cardiol; 2015 Nov; 199():319-25. PubMed ID: 26241637
[TBL] [Abstract][Full Text] [Related]
3. Impact of Triple Therapy in Elderly Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention.
Sambola A; Mutuberría M; García Del Blanco B; Alonso A; Barrabés JA; Bueno H; Alfonso F; Cequier A; Zueco J; Rodríguez-Leor O; Tornos P; García-Dorado D
PLoS One; 2016; 11(1):e0147245. PubMed ID: 26808678
[TBL] [Abstract][Full Text] [Related]
4. CHADS2, CHA2DS2-VASc and HAS-BLED as predictors of outcome in patients with atrial fibrillation undergoing percutaneous coronary intervention.
Puurunen MK; Kiviniemi T; Schlitt A; Rubboli A; Dietrich B; Karjalainen P; Nyman K; Niemelä M; Lip GY; Airaksinen KE
Thromb Res; 2014 Apr; 133(4):560-6. PubMed ID: 24461143
[TBL] [Abstract][Full Text] [Related]
5. Dual antiplatelet therapy versus oral anticoagulation plus dual antiplatelet therapy in patients with atrial fibrillation and low-to-moderate thromboembolic risk undergoing coronary stenting: design of the MUSICA-2 randomized trial.
Sambola A; Montoro JB; Del Blanco BG; Llavero N; Barrabés JA; Alfonso F; Bueno H; Cequier A; Serra A; Zueco J; Sabaté M; Rodríguez-Leor O; García-Dorado D
Am Heart J; 2013 Oct; 166(4):669-75. PubMed ID: 24093846
[TBL] [Abstract][Full Text] [Related]
6. Balancing the Risk of Bleeding and Stroke in Patients With Atrial Fibrillation After Percutaneous Coronary Intervention (from the AVIATOR Registry).
Mennuni MG; Halperin JL; Bansilal S; Schoos MM; Theodoropoulos KN; Meelu OA; Sartori S; Giacoppo D; Bernelli C; Moreno PR; Krishnan P; Baber U; Lucarelli C; Dangas GD; Sharma SK; Kini AS; Tamburino C; Chieffo A; Colombo A; Presbitero P; Mehran R
Am J Cardiol; 2015 Jul; 116(1):37-42. PubMed ID: 25956624
[TBL] [Abstract][Full Text] [Related]
7. Triple Antithrombotic Therapy after Percutaneous Coronary Intervention (PCI) in Patients with Indication for Oral Anticoagulation: Data from a Single Center Registry.
Staudacher DL; Kaiser M; Hehrlein C; Bode C; Ahrens I
PLoS One; 2015; 10(10):e0140101. PubMed ID: 26439131
[TBL] [Abstract][Full Text] [Related]
8. Value of DAPT score to predict adverse outcome in patients with atrial fibrillation undergoing percutaneous coronary intervention: A post-hoc analysis from the AFCAS registry.
Nammas W; Kiviniemi T; Schlitt A; Rubboli A; Valencia J; Lip GYH; Karjalainen PP; Biancari F; Juhani Airaksinen KE
Int J Cardiol; 2018 Feb; 253():35-39. PubMed ID: 29306469
[TBL] [Abstract][Full Text] [Related]
9. Young Male Patients with Atrial Fibrillation and CHA2DS2-VASc Score of 1 May Not Need Anticoagulants: A Nationwide Population-Based Study.
Chan YH; Wu LS; Chang SH; Lee HF; Liu JR; See LC; Yeh YH; Kuo CT
PLoS One; 2016; 11(3):e0151485. PubMed ID: 26986069
[TBL] [Abstract][Full Text] [Related]
10. Renal dysfunction, stroke risk scores (CHADS2, CHA2DS2-VASc, and R2CHADS2), and the risk of thromboembolic events after catheter ablation of atrial fibrillation: the Leipzig Heart Center AF Ablation Registry.
Kornej J; Hindricks G; Kosiuk J; Arya A; Sommer P; Husser D; Rolf S; Richter S; Piorkowski C; Gaspar T; Lip GY; Bollmann A
Circ Arrhythm Electrophysiol; 2013 Oct; 6(5):868-74. PubMed ID: 24047706
[TBL] [Abstract][Full Text] [Related]
11. Anticoagulant and antiplatelet therapy use in 426 patients with atrial fibrillation undergoing percutaneous coronary intervention and stent implantation implications for bleeding risk and prognosis.
Ruiz-Nodar JM; Marín F; Hurtado JA; Valencia J; Pinar E; Pineda J; Gimeno JR; Sogorb F; Valdés M; Lip GY
J Am Coll Cardiol; 2008 Feb; 51(8):818-25. PubMed ID: 18294566
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of GRACE and CHA2DS2-VASc score among patients with atrial fibrillation undergoing percutaneous coronary intervention.
Guo T; Xi Z; Qiu H; Wang Y; Zheng J; Dou K; Xu B; Qiao S; Yang W; Gao R
Ann Med; 2021 Dec; 53(1):2215-2224. PubMed ID: 34791980
[TBL] [Abstract][Full Text] [Related]
13. Assessment of the CHA2DS2-VASc Score in Predicting Ischemic Stroke, Thromboembolism, and Death in Patients With Heart Failure With and Without Atrial Fibrillation.
Melgaard L; Gorst-Rasmussen A; Lane DA; Rasmussen LH; Larsen TB; Lip GY
JAMA; 2015 Sep; 314(10):1030-8. PubMed ID: 26318604
[TBL] [Abstract][Full Text] [Related]
14. CHA
D'Souza M; Carlson N; Fosbøl E; Lamberts M; Smedegaard L; Nielsen D; Torp-Pedersen C; Gislason G; Schou M
Eur J Prev Cardiol; 2018 Apr; 25(6):651-658. PubMed ID: 29482441
[TBL] [Abstract][Full Text] [Related]
15. [A comparison of CAS risk model and CHA
Deng JL; He L; Jiang C; Lai YW; Long DY; Sang CH; Jia CQ; Feng L; Li X; Ning M; Hu R; Dong JZ; Du X; Tang RB; Ma CS
Zhonghua Xin Xue Guan Bing Za Zhi; 2022 Sep; 50(9):888-894. PubMed ID: 36096706
[No Abstract] [Full Text] [Related]
16. The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0-1: a nationwide cohort study.
Olesen JB; Torp-Pedersen C; Hansen ML; Lip GY
Thromb Haemost; 2012 Jun; 107(6):1172-9. PubMed ID: 22473219
[TBL] [Abstract][Full Text] [Related]
17. Bridging therapy with low molecular weight heparin in patients with atrial fibrillation undergoing percutaneous coronary intervention with stent implantation: the AFCAS study.
Kiviniemi T; Airaksinen KE; Rubboli A; Biancari F; Valencia J; Lip GY; Karjalainen PP; Weber M; Laine M; Kirchhof P; Schlitt A;
Int J Cardiol; 2015 Mar; 183():105-10. PubMed ID: 25662060
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the efficacy and safety of dual antiplatelet therapy with or without warfarin in patients with a clinical indication for DAPT and chronic anticoagulation: A meta-analysis of observational studies.
Bavishi C; Koulova A; Bangalore S; Sawant A; Chatterjee S; Ather S; Valencia J; Sarafoff N; Rubboli A; Airaksinen JK; Lip GY; Tamis-Holland JE
Catheter Cardiovasc Interv; 2016 Jul; 88(1):E12-22. PubMed ID: 26354765
[TBL] [Abstract][Full Text] [Related]
19. The management of patients with atrial fibrillation undergoing percutaneous coronary intervention with stent implantation: in-hospital-data from the Atrial Fibrillation undergoing Coronary Artery Stenting study.
Schlitt A; Rubboli A; Lip GY; Lahtela H; Valencia J; Karjalainen PP; Weber M; Laine M; Kirchhof P; Niemelä M; Vikman S; Buerke M; Airaksinen KE;
Catheter Cardiovasc Interv; 2013 Dec; 82(7):E864-70. PubMed ID: 23765437
[TBL] [Abstract][Full Text] [Related]
20. Time in therapeutic range and major adverse outcomes in atrial fibrillation patients undergoing percutaneous coronary intervention: The Atrial Fibrillation Undergoing Coronary Artery Stenting (AFCAS) registry.
Proietti M; Airaksinen KEJ; Rubboli A; Schlitt A; Kiviniemi T; Karjalainen PP; Lip GY;
Am Heart J; 2017 Aug; 190():86-93. PubMed ID: 28760217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
